Using insulin pump therapy in poorly controlled type 2 diabetes

Diabetes Educator

Volumn 36, Issue 4, 2010, Pages 657-665

  Wolff McDonagh, Phyllis ^a,b   Kaufmann, Judith ^a   Foreman, Stephen ^a   Wisotsky, Steven ^a   Wisotsky, Jo Ann ^a   Wexler, Craig ^a  

^a ROBERT MORRIS UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; ARTICLE; BLOOD; DIABETES MELLITUS; FEMALE; HOMEOSTASIS; HUMAN; INSULIN INFUSION; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT EDUCATION; UNITED STATES; UTILIZATION REVIEW;

ADULT; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; OBESITY; PATIENT EDUCATION AS TOPIC; UNITED STATES;

EID: 78149374697     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721710374369     Document Type: Article

References (28)

1. American Diabetes Association. Diabetes statistics. Available at: http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed November 3, 2009.
2. Herman WH, Ilag LL, Johnson SL,et al.A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28(7): 1568-1573.
3. Gray A., Clarke P., Farmer A., Holman R. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ. 2002;325(7369):860. Available at: http://www.bmj.com/cgi/reprint/325/7369/860. Accessed November 3, 2009.
4. Shichiri M., Kishikawa H., Ohkubo Y., Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21-B29.
5. Minshall ME, Roze S., Palmer AJ,et al.Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States. Clin Ther. 2005;27(6):940-950.
6. Robard HW, Blonde L., Braithwaite SS,et al.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Practice. 2007;13(Suppl 1):1-68.
7. Boyle ME Optimizing the treatment of type 2 diabetes using current and future insulin technologies. Medsurg Nurs. 2008;17(6):383-390.
8. Berthe E., Lireux B., Coffin C.,et al.Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm Metab Res. 2007;39:224-229.
9. Hsu SR, Lin SD, Tu ST Metabolic control with insulin pump therapy: preliminary experience. J Chin Med Assoc. 2008;71(7): 353-356.
10. Monami M., Lamanna C., Marchionni N., Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis. Exp Clin Endocrinol Diabetes. 2009;117(5):220-222.
11. Nielsen S., Kain D., Szudzik E., Dhindsa S., Garg R., Dandona P. Use of continuous subcutaneous insulin infusion pump in patients with type 2 diabetes mellitus. Diabetes Educ. 2005;31(6):843-848.
12. Raskin P., Bode BW, Marks JB,et al.Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26(9):2598-2603.
13. Wainstein J., Metzger M., Boaz M.,et al.Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients. Diabet Med. 2005;22:1037-1046.
14. Wainstein J., Metzger M., Wexler ID, Cohen J., Raz I. The use of continuous insulin delivery systems in severely insulin-resistant patients [letter]. Diabetes Care. 2001;24(7):1299.
15. Centers for Medicare and Medicaid Services. Infusion Pumps: C-peptide Levels as a Criterion for Use. Medicare National Coverage Determinations Manual: Coverage Determinations, revisions 27, 280.14 infusion pumps. CMS publication 100-03. Baltimore, Maryland: Centers for Medicare and Medicaid Services, US Department of Health and Human Services; 2005.
16. Sari R., Balci MK Relationship between C peptide and chronic complications in type 2 diabetes mellitus. J Natl Med Assoc. 2005;97(8):1113-1118.
17. Lane WS, Cochran EK, Jackson JA,et al.High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009;15(1):71-79.
18. Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care. 2008;31(Suppl 2):S140-S145.
19. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596-615.
20. Wagner EH, Sandhu N., Newton KM, McCulloch DK, Ramsey SD, Grothaus LC Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285(2):182-189.
21. Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy. 2008;6 (2-3):103-112.
22. Potti LG, Haines ST,et al.Continuous subcutaneous insulin infusion therapy: a primer on insulin pumps. J Am Pharm Assoc. 2009;49:e1-e17.
23. Zhou H., Isaman DJ, Messinger S.,et al.A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care. 2005;28(12):2856-2863.
24. Henry R., Gumbiner B., Ditzler T.,et al.Intensive conventional insulin therapy for type 2 diabetes: metabolic effects during a 6 month outpatient trial. Diabetes Care. 1993;16:21-27.
25. Kanakis SJ, Watts C., Leichter SB The business of insulin pumps in diabetes care: clinical and economic considerations. Clinical Diabetes. 2002;20(4):214-216.
26. Neumiller JJ, Odegard PS, Wysham CH Update on insulin management of type 2 diabetes. Diabetes Spectrum. 2009;22(2):85-91.
27. Renner R., Pfützner A., Trautmann M.,et al.Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Diabetes Care. 1999;22(5):784-788.
28. Melki V., Renard E., Lassmann-Vague V.,et al.Improvement of HbA1C and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care. 1998;21(6): 977-982.